Chemotherapy-Induced Peripheral Neuropathy: A Patient Overview

Chemotherapy-induced peripheral neuropathy (CIPN) is nerve damage caused by certain chemotherapy medications used to treat cancer. The condition typically produces numbness, tingling, burning pain, or sensitivity in the hands and feet that begins during or after treatment. This page explains which chemotherapy regimens cause CIPN, what patients experience, how it is diagnosed, and what the literature shows about recovery.

Who develops CIPN

CIPN is not caused by all chemotherapy regimens — it is specifically associated with agents that have neurotoxic effects on peripheral nerves. Seretny and colleagues published a systematic review and meta-analysis in a 2014 Pain paper establishing the broad prevalence figures: 68.1% of patients have CIPN within the first month after completing neurotoxic chemotherapy, 60.0% at three months, and 30.0% at six months or later (PMID 25261162). These are averages across regimens; actual rates vary substantially based on which medication was used, cumulative dose, and individual patient factors.

Risk factors that increase CIPN likelihood include the specific neurotoxic agent, the cumulative dose, dose intensity, treatment duration, pre-existing peripheral neuropathy (from diabetes or alcohol use), older age in some studies, and inherited susceptibility factors. Patients who develop CIPN during treatment may have the regimen modified — dose reduction, delay, or agent substitution — based on symptom severity.

Which chemotherapy regimens cause CIPN

Several classes of chemotherapy agents are associated with peripheral neuropathy, each producing a somewhat distinct pattern of nerve damage. Park and colleagues provided a critical analysis of CIPN across these classes in a 2013 CA: A Cancer Journal for Clinicians paper (PMID 24590861).

Platinum compounds include cisplatin, oxaliplatin, and carboplatin, widely used in colorectal, ovarian, lung, head and neck, and testicular cancers. Oxaliplatin and cisplatin are particularly associated with CIPN; carboplatin causes neuropathy less frequently. Platinum agents predominantly affect large sensory fibers and the dorsal root ganglia.

Taxanes include paclitaxel (Taxol), nab-paclitaxel (Abraxane), and docetaxel (Taxotere), widely used in breast, ovarian, and lung cancers. Paclitaxel is associated with more frequent and more severe CIPN than docetaxel. Taxanes affect both large and small sensory fibers.

Vinca alkaloids include vincristine, vinblastine, and vinorelbine. Vincristine, used in childhood leukemias and lymphomas as well as some adult lymphomas, is particularly associated with CIPN. It can produce both sensory and motor symptoms.

Bortezomib, a proteasome inhibitor used in multiple myeloma, is strongly associated with peripheral neuropathy that can be particularly painful. Thalidomide and related immunomodulatory drugs (lenalidomide, pomalidomide) are used in multiple myeloma; thalidomide is most strongly associated with CIPN of this class. Other agents associated with CIPN include eribulin, ixabepilone, and certain antibody-drug conjugates.

The oxaliplatin acute cold-induced pattern

Oxaliplatin produces a distinctive acute neuropathy pattern that is separate from the cumulative chronic neuropathy that develops with continued treatment. Within hours of an oxaliplatin infusion, patients commonly experience cold-triggered tingling, numbness, or pain in the hands, feet, jaw, and throat. Cold drinks, cold foods, cold air, or handling refrigerated items can trigger or worsen the sensations.

The acute symptoms typically resolve within hours to days. The cumulative chronic neuropathy that develops over many cycles is a separate process with a different trajectory. Pachman and colleagues characterized both patterns in detail in a 2015 Journal of Clinical Oncology paper reporting trial N08CB, including the relationship between cumulative dose and chronic symptoms and the recovery curve after treatment ends (PMID 26282635).

What patients experience

CIPN typically begins symmetrically in the hands and feet — particularly the fingertips and toes. Early symptoms include tingling, pins and needles, numbness, and altered sensation. As cumulative dose increases, symptoms may progress to burning pain, allodynia (pain from light touch that would not normally be painful), reduced fine motor control affecting tasks like buttoning clothing, and balance problems.

Sensory symptoms predominate in most CIPN. Motor weakness is less common but can occur with certain agents, particularly vincristine. A clinically important feature is the "coasting" phenomenon — the continuation or worsening of symptoms after chemotherapy ends, before stabilization or improvement begins. Coasting is most often described with platinum-based regimens and can last weeks to months. Cavaletti and Marmiroli reviewed the biology and clinical features of CIPN in a 2010 Nature Reviews Neurology paper (PMID 21060341).

The impact on daily function varies. Mild CIPN may produce intermittent symptoms without significant functional impairment. Severe CIPN can interfere with walking, balance, manual tasks, sleep, and quality of life. Staff and colleagues reviewed the current understanding of CIPN biology and the clinical spectrum in a 2017 Annals of Neurology paper (PMID 28486769).

How CIPN is diagnosed

CIPN is typically a clinical diagnosis based on the temporal relationship between neurotoxic chemotherapy and consistent symptoms. Oncologists, neurologists, and primary care physicians can recognize the typical pattern from history and physical examination.

Several standardized assessment tools exist. The Total Neuropathy Score (TNS), described by Cavaletti and colleagues in a 2007 Journal of the Peripheral Nervous System paper, combines symptoms, examination findings, and electrodiagnostic measurements (PMID 17868247). Patient-reported outcome measures include the FACT/GOG-Ntx subscale and the EORTC QLQ-CIPN20; Cavaletti and colleagues validated these measures against each other in a 2013 Annals of Oncology standardization study (PMID 22910842). Common Terminology Criteria for Adverse Events (CTCAE) grading, from grade 1 through grade 4, is widely used in oncology trials to characterize severity.

In some cases, neurologic consultation and electrodiagnostic testing are added to confirm the pattern of nerve involvement, rule out coexisting causes, or evaluate atypical features. Skin punch biopsy may be added when small-fiber involvement is suspected.

What the literature shows about recovery

The recovery trajectory varies substantially by agent. Seretny's meta-analysis documented approximately 30% of patients with persistent CIPN at six months, with longer-term follow-up studies showing symptoms continuing for years in a meaningful subset. Grisold and colleagues reviewed the agent-by-agent recovery patterns in a 2012 Neuro-Oncology paper (PMID 23095830).

Platinum-induced neuropathy from cisplatin can be long-lasting. Oxaliplatin chronic neuropathy improves in many patients over months to years, though a subset has persistent symptoms — Beijers and colleagues reviewed the chronic oxaliplatin neuropathy literature in a 2014 Supportive Care in Cancer paper (PMID 24728618). Taxane-induced neuropathy improves in many patients over time, with paclitaxel typically having a longer recovery period than docetaxel. Bortezomib-induced neuropathy can be partially or completely reversible in some patients with treatment modification.

The American Society of Clinical Oncology (ASCO) issued a 2020 guideline update on the prevention and management of CIPN in survivors of adult cancers, published by Loprinzi and colleagues (PMID 32663120). The guideline addresses both which agents have evidence for reducing CIPN incidence (currently limited) and which treatments have evidence for symptomatic management of established CIPN. Our clinical guide on CIPN, reviewed by a physician on our Medical Advisory Board, addresses the treatment landscape in detail.

For evidence-based information about treatment options for CIPN

A separate clinical guide on this site covers the treatment landscape for CIPN — including the ASCO guideline recommendations, dose modification strategies, and survivorship management — and is reviewed by a board-certified physician on our Medical Advisory Board before publication.

⏳ Under review: A clinical guide covering treatment options for this condition is currently under physician review and will publish soon.

Frequently asked questions